Beta Alethine in Treating Patients With Low-Grade Lymphoma
- Conditions
- Lymphoma
- Registration Number
- NCT00007839
- Lead Sponsor
- LifeTime Pharmaceuticals
- Brief Summary
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have low-grade lymphoma.
- Detailed Description
OBJECTIVES:
* Determine the antitumor effects of low-dose beta-alethine in patients with low grade B-cell lymphoma.
* Assess the effects of this regimen on delayed-type hypersensitivity in these patients.
* Assess the safety of this regimen in this patient population.
OUTLINE: This is an multicenter study.
Patients receive low-dose beta-alethine subcutaneously once every 2 weeks for a total of 6 doses in the absence of unacceptable toxicity. Patients with no evidence of tumor progression may receive additional courses of therapy.
Patients are followed for 2 weeks from the last dose or for a minimum of 30 days if they withdraw due to an adverse event.
PROJECTED ACCRUAL: Approximately 13-37 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Victory Over Cancer
🇺🇸Rockville, Maryland, United States
Victory Over Cancer🇺🇸Rockville, Maryland, United States